Amgen Inc

자세한 내용은 Amgen Inc 회사

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.

회사 정보

종목 코드 AMGN

회사 이름Amgen Inc

상장일Jun 17, 1983

CEOMr. Robert A. (Bob) Bradway

직원 수28000

유형Ordinary Share

회계 연도 종료Jun 17

주소One Amgen Center Drive

도시THOUSAND OAKS

증권 거래소NASDAQ Global Select Consolidated

국가United States of America

우편 번호91320-1799

전화18054471000

웹사이트https://www.amgen.com/

종목 코드 AMGN

상장일Jun 17, 1983

CEOMr. Robert A. (Bob) Bradway

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Robert A. (Bob) Bradway

Chairman of the Board, President, Chief Executive Officer

566.37K

+1.52%

Mr. Esteban Santos

Executive Vice President - Operations

69.05K

+3.06%

Mr. Murdo Gordon

Executive Vice President - Global Commercial Operations

41.70K

+6.10%

Dr. Tyler Jacks

Independent Director

17.19K

+4.94%

Mr. Derek Miller

Senior Vice President - Human Resources

9.93K

+6.57%

Ms. Rachna Khosla

Senior Vice President - Business Development

7.78K

-16.17%

Dr. Brian J. Druker, M.D.

Independent Director

7.57K

+11.97%

Dr. Wanda M. Austin, Ph.D.

Independent Director

7.35K

+12.36%

Ms. Nancy A. Grygiel

Senior Vice President, Chief Compliance Officer

6.04K

-17.35%

Ms. Amy E. Miles

Independent Director

4.84K

+20.06%

이름

이름/직위

직위

주식 보유

변동

Mr. Robert A. (Bob) Bradway

Chairman of the Board, President, Chief Executive Officer

566.37K

+1.52%

Mr. Esteban Santos

Executive Vice President - Operations

69.05K

+3.06%

Mr. Murdo Gordon

Executive Vice President - Global Commercial Operations

41.70K

+6.10%

Dr. Tyler Jacks

Independent Director

17.19K

+4.94%

Mr. Derek Miller

Senior Vice President - Human Resources

9.93K

+6.57%

Ms. Rachna Khosla

Senior Vice President - Business Development

7.78K

-16.17%

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

사업별USD

이름

수익

비율

Other products

1.65B

20.21%

Prolia

1.10B

13.49%

Repatha

656.00M

8.05%

XGEVA

566.00M

6.95%

Enbrel

510.00M

6.26%

기타

3.67B

45.05%

지역별USD

이름

수익

비율

US

5.34B

65.55%

ROW

2.09B

25.64%

사업별

지역별

사업별USD

이름

수익

비율

Other products

1.65B

20.21%

Prolia

1.10B

13.49%

Repatha

656.00M

8.05%

XGEVA

566.00M

6.95%

Enbrel

510.00M

6.26%

기타

3.67B

45.05%

주식 보유 통계

마지막 업데이트: Tue, Aug 19

주주

주주 유형

주주

비율

The Vanguard Group, Inc.

9.93%

State Street Global Advisors (US)

5.45%

BlackRock Institutional Trust Company, N.A.

5.36%

Capital International Investors

3.51%

Capital World Investors

3.13%

기타

72.62%

주주

비율

The Vanguard Group, Inc.

9.93%

State Street Global Advisors (US)

5.45%

BlackRock Institutional Trust Company, N.A.

5.36%

Capital International Investors

3.51%

Capital World Investors

3.13%

기타

72.62%

주주 유형

주주

비율

Investment Advisor

53.19%

Investment Advisor/Hedge Fund

19.47%

Research Firm

4.96%

Pension Fund

2.21%

Bank and Trust

1.96%

Sovereign Wealth Fund

1.18%

Insurance Company

0.61%

Hedge Fund

0.50%

Individual Investor

0.17%

기타

15.75%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

4453

451.65M

83.89%

+6.94M

2025Q1

4519

453.49M

84.33%

+5.91M

2024Q4

4466

443.40M

82.54%

+89.78K

2024Q3

4316

438.01M

81.42%

-5.13M

2024Q2

4284

437.79M

81.61%

-4.94M

2024Q1

4192

436.25M

81.40%

-5.11M

2023Q4

4150

435.28M

81.36%

+42.25K

2023Q3

3990

429.94M

80.36%

-4.48M

2023Q2

3936

426.14M

79.65%

-4.34M

2023Q1

3951

427.29M

80.00%

-4.36M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

The Vanguard Group, Inc.

52.63M

9.79%

+145.69K

+0.28%

Mar 31, 2025

State Street Global Advisors (US)

29.18M

5.43%

-254.42K

-0.86%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

28.50M

5.3%

-289.51K

-1.01%

Mar 31, 2025

Capital International Investors

15.13M

2.81%

+2.92M

+23.93%

Mar 31, 2025

Capital World Investors

16.70M

3.11%

+10.21M

+157.12%

Mar 31, 2025

Geode Capital Management, L.L.C.

12.73M

2.37%

+252.31K

+2.02%

Mar 31, 2025

Charles Schwab Investment Management, Inc.

12.21M

2.27%

-999.66K

-7.57%

Mar 31, 2025

Invesco Capital Management (QQQ Trust)

11.11M

2.07%

-33.38K

-0.30%

Jun 30, 2025

PRIMECAP Management Company

12.39M

2.3%

-613.83K

-4.72%

Mar 31, 2025

Morgan Stanley Smith Barney LLC

8.73M

1.62%

+352.70K

+4.21%

Mar 31, 2025

관련 ETF

마지막 업데이트: Wed, Aug 6

이름

비율

VanEck Biotech ETF

16.29%

FT Vest DJIA Dogs 10 Target Income ETF

9.8%

ProShares Ultra Nasdaq Biotechnology

7.47%

Invesco Nasdaq Biotechnology ETF

6.93%

iShares Biotechnology ETF

6.85%

Amplify Weight Loss Drug & Treatment ETF

6.68%

Invesco Biotechnology & Genome ETF

5.28%

Invesco Pharmaceuticals ETF

5.16%

Invesco Dow Jones Industrial Average Dividend ETF

5.11%

Proshares UltraPro Dow 30

4.3%

VanEck Biotech ETF

비율16.29%

FT Vest DJIA Dogs 10 Target Income ETF

비율9.8%

ProShares Ultra Nasdaq Biotechnology

비율7.47%

Invesco Nasdaq Biotechnology ETF

비율6.93%

iShares Biotechnology ETF

비율6.85%

Amplify Weight Loss Drug & Treatment ETF

비율6.68%

Invesco Biotechnology & Genome ETF

비율5.28%

Invesco Pharmaceuticals ETF

비율5.16%

Invesco Dow Jones Industrial Average Dividend ETF

비율5.11%

Proshares UltraPro Dow 30

비율4.3%

주식 배당금

지난 5년 동안 총 21.35B USD의 배당금이 분배되었습니다.

날짜

배당금

기준일

지급일

배당락일

Dec 10, 2024

AMGN.NB Interim Cash Dividend of gross USD 2.38 paid on Mar 07, 2025 going ex on Feb 14, 2025

Feb 14, 2025

Mar 07, 2025

Feb 14, 2025

Oct 25, 2024

AMGN.NB Final Cash Dividend of gross USD 2.25 paid on Dec 09, 2024 going ex on Nov 18, 2024

Nov 18, 2024

Dec 09, 2024

Nov 18, 2024

Aug 02, 2024

AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Sep 06, 2024 going ex on Aug 16, 2024

Aug 16, 2024

Sep 06, 2024

Aug 16, 2024

Mar 06, 2024

AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Jun 07, 2024 going ex on May 16, 2024

May 17, 2024

Jun 07, 2024

May 16, 2024

Dec 12, 2023

AMGN.NB Interim Cash Dividend of gross USD 2.25 paid on Mar 07, 2024 going ex on Feb 15, 2024

Feb 16, 2024

Mar 07, 2024

Feb 15, 2024

Oct 24, 2023

AMGN.NB Final Cash Dividend of gross USD 2.13 paid on Dec 08, 2023 going ex on Nov 16, 2023

Nov 17, 2023

Dec 08, 2023

Nov 16, 2023

Aug 01, 2023

AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Sep 08, 2023 going ex on Aug 17, 2023

Aug 18, 2023

Sep 08, 2023

Aug 17, 2023

Mar 07, 2023

AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Jun 08, 2023 going ex on May 17, 2023

May 18, 2023

Jun 08, 2023

May 17, 2023

Dec 12, 2022

AMGN.NB Interim Cash Dividend of gross USD 2.13 paid on Mar 08, 2023 going ex on Feb 14, 2023

Feb 15, 2023

Mar 08, 2023

Feb 14, 2023

Oct 28, 2022

AMGN.NB Final Cash Dividend of gross USD 1.94 paid on Dec 08, 2022 going ex on Nov 16, 2022

Nov 17, 2022

Dec 08, 2022

Nov 16, 2022

주식 분할

날짜

유형

비율

데이터 없음

날짜

유형

비율

데이터 없음

288.470USD

Amgen Inc

288.470

개요

회사

금융